Jefferies Group LLC Reiterates Buy Rating for Atara Biotherapeutics, Inc. (ATRA)

Jefferies Group LLC restated their buy rating on shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) in a research report report published on Thursday, October 5th. The firm currently has a $30.00 target price on the biotechnology company’s stock.

ATRA has been the topic of several other reports. Zacks Investment Research raised Atara Biotherapeutics from a sell rating to a hold rating and set a $15.00 price objective on the stock in a research note on Tuesday, August 22nd. ValuEngine lowered Atara Biotherapeutics from a sell rating to a strong sell rating in a research note on Tuesday, August 1st. William Blair reissued an outperform rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. BidaskClub lowered Atara Biotherapeutics from a hold rating to a sell rating in a research report on Tuesday, August 22nd. Finally, Canaccord Genuity set a $47.00 price target on Atara Biotherapeutics and gave the stock a buy rating in a research report on Monday, August 7th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $24.40.

Atara Biotherapeutics (NASDAQ ATRA) opened at 14.55 on Thursday. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $23.00. The stock has a 50 day moving average of $15.62 and a 200 day moving average of $15.37. The company’s market cap is $444.63 million.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.05). On average, analysts expect that Atara Biotherapeutics will post ($3.91) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Jefferies Group LLC Reiterates Buy Rating for Atara Biotherapeutics, Inc. (ATRA)” was posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://baseballnewssource.com/markets/atara-biotherapeutics-inc-atra-stock-rating-reaffirmed-by-jefferies-group-llc/1701517.html.

In related news, CEO Isaac E. Ciechanover sold 5,500 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $16.49, for a total transaction of $90,695.00. Following the completion of the sale, the chief executive officer now owns 731,859 shares in the company, valued at approximately $12,068,354.91. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $14.67, for a total value of $64,548.00. Following the sale, the chief executive officer now owns 731,859 shares of the company’s stock, valued at approximately $10,736,371.53. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,509 shares of company stock valued at $906,736. 16.20% of the stock is owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its position in shares of Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after acquiring an additional 610 shares during the period. American International Group Inc. lifted its position in shares of Atara Biotherapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 948 shares during the period. Teachers Advisors LLC lifted its position in shares of Atara Biotherapeutics by 2.4% in the 2nd quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock worth $660,000 after acquiring an additional 1,110 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,369 shares during the period. Finally, Alps Advisors Inc. lifted its position in shares of Atara Biotherapeutics by 5.8% in the 2nd quarter. Alps Advisors Inc. now owns 26,274 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 1,445 shares during the period. Institutional investors own 82.95% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.